No Data
Fuxiang Pharmaceutical: 2024 Annual Report
Fuxiang Pharmaceutical: First Quarter Report 2025
Fuxiang Pharmaceutical: 2024 Annual Report Summary
Jiangxi Fushine Pharmaceutical (300497.SZ): In the first quarter, net income was 2.2388 million yuan, an increase of 52.46% year-on-year.
Gelonghui, April 25丨Jiangxi Fushine Pharmaceutical (300497.SZ) announced its first quarter report for 2025, with revenue of 0.234 billion yuan, a year-on-year decrease of 31.35%; net income attributable to shareholders of the listed company was 2.2388 million yuan, a year-on-year increase of 52.46%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -22.5996 million yuan; basic EPS was 0.004 yuan.
Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Business Is Yet to Catch Up With Its Share Price
Fushine Pharma Completes Establishment of Subsidiary
The Market Doesn't Like What It Sees From Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Revenues Yet
